|MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling|
JA Engelman, K Zejnullahu, T Mitsudomi, Y Song, C Hyland, JO Park, ...
science 316 (5827), 1039-1043, 2007
|First-line crizotinib versus chemotherapy in ALK-positive lung cancer|
BJ Solomon, T Mok, DW Kim, YL Wu, K Nakagawa, T Mekhail, E Felip, ...
N Engl j Med 371, 2167-2177, 2014
|Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC|
MA Socinski, RM Jotte, F Cappuzzo, F Orlandi, D Stroyakovskiy, ...
New England Journal of Medicine 378 (24), 2288-2301, 2018
|Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective …|
W De Roock, B Claes, D Bernasconi, J De Schutter, B Biesmans, ...
The lancet oncology 11 (8), 753-762, 2010
|First-line nivolumab in stage IV or recurrent non–small-cell lung cancer|
DP Carbone, M Reck, L Paz-Ares, B Creelan, L Horn, M Steins, E Felip, ...
New England Journal of Medicine 376 (25), 2415-2426, 2017
|Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non–small-cell lung cancer|
F Cappuzzo, FR Hirsch, E Rossi, S Bartolini, GL Ceresoli, L Bemis, ...
Journal of the National Cancer Institute 97 (9), 643-655, 2005
|Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study|
F Cappuzzo, T Ciuleanu, L Stelmakh, S Cicenas, A Szczésna, E Juhász, ...
The lancet oncology 11 (6), 521-529, 2010
|Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase …|
NA Rizvi, J Mazières, D Planchard, TE Stinchcombe, GK Dy, SJ Antonia, ...
The lancet oncology 16 (3), 257-265, 2015
|Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer|
M Peifer, L Fernández-Cuesta, ML Sos, J George, D Seidel, LH Kasper, ...
Nature genetics 44 (10), 1104-1110, 2012
|Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy …|
EB Garon, TE Ciuleanu, O Arrieta, K Prabhash, KN Syrigos, T Goksel, ...
The Lancet 384 (9944), 665-673, 2014
|Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small …|
H West, M McCleod, M Hussein, A Morabito, A Rittmeyer, HJ Conter, ...
The Lancet Oncology 20 (7), 924-937, 2019
|Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer|
J Weiss, ML Sos, D Seidel, M Peifer, T Zander, JM Heuckmann, RT Ullrich, ...
Science translational medicine 2 (62), 62ra93-62ra93, 2010
|Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in …|
M Reck, TSK Mok, M Nishio, RM Jotte, F Cappuzzo, F Orlandi, ...
The Lancet Respiratory Medicine 7 (5), 387-401, 2019
|Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab|
K Yonesaka, K Zejnullahu, I Okamoto, T Satoh, F Cappuzzo, J Souglakos, ...
Science translational medicine 3 (99), 99ra86-99ra86, 2011
|Increased MET gene copy number negatively affects survival of surgically resected non–small-cell lung cancer patients|
F Cappuzzo, A Marchetti, M Skokan, E Rossi, S Gajapathy, L Felicioni, ...
Journal of clinical oncology 27 (10), 1667, 2009
|PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients|
A D'incecco, M Andreozzi, V Ludovini, E Rossi, A Capodanno, L Landi, ...
British journal of cancer 112 (1), 95-102, 2015
|Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung CancerROS1 Gene Fusions in NSCLC|
KD Davies, AT Le, MF Theodoro, MC Skokan, DL Aisner, EM Berge, ...
Clinical Cancer Research 18 (17), 4570-4579, 2012
|Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor–positive non–small-cell lung cancer patients|
F Cappuzzo, M Varella-Garcia, H Shigematsu, I Domenichini, S Bartolini, ...
Journal of clinical oncology 23 (22), 5007-5018, 2005
|Akt phosphorylation and gefitinib efficacy in patients with advanced non–small-cell lung cancer|
F Cappuzzo, E Magrini, GL Ceresoli, S Bartolini, E Rossi, V Ludovini, ...
Journal of the National Cancer Institute 96 (15), 1133-1141, 2004
|Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial|
GL Ceresoli, F Cappuzzo, V Gregorc, S Bartolini, L Crino, E Villa
Annals of Oncology 15 (7), 1042-1047, 2004